| Title |
Acute Kidney Injury With the RenalGuard System in Patients Undergoing Transcatheter Aortic Valve Replacement The PROTECT-TAVI Trial (PROphylactic effecT of furosEmide-induCed diuresis with matched isotonic intravenous hydraTion in Transcatheter Aortic Valve Implantation)
|
|---|---|
| Published in |
JACC: Cardiovascular Interventions, September 2015
|
| DOI | 10.1016/j.jcin.2015.07.012 |
| Pubmed ID | |
| Authors |
Marco Barbanti, Simona Gulino, Piera Capranzano, Sebastiano Immè, Carmelo Sgroi, Claudia Tamburino, Yohei Ohno, Guilherme F. Attizzani, Martina Patanè, Rita Sicuso, Gerlando Pilato, Alessio Di Landro, Denise Todaro, Emanuela Di Simone, Andrea Picci, Giuliana Giannetto, Giuliano Costa, Wanda Deste, Daniela Giannazzo, Carmelo Grasso, Davide Capodanno, Corrado Tamburino |
| Abstract |
The purpose of this study was to investigate the effect of the RenalGuard System (PLC Medical Systems, Milford, Massachusetts) on prevention of acute kidney injury (AKI) in patients undergoing transcatheter aortic valve replacement (TAVR). TAVR is associated with varying degrees of post-procedural AKI. The RenalGuard System is a dedicated device designed for contrast-induced AKI prevention. Whether this device is also effective in patients with severe aortic stenosis undergoing TAVR is unexplored. The present is an investigator-driven, single-center, prospective, open-label, registry-based randomized study that used the TAVR institutional registry of the Ferrarotto Hospital in Catania, Italy, as the platform for randomization, data collection, and follow-up assessment. A total of 112 consecutive patients undergoing TAVR were randomly assigned to hydration with normal saline solution controlled by the RenalGuard system and furosemide (RenalGuard group) or normal saline solution (control group). The primary endpoint was the incidence of Valve Academic Research Consortium-defined AKI in the first 72 h after the procedure. The AKI rate was lower in the RenalGuard group than in the control group (n = 3 [5.4%] vs. n =14 [25.0%], respectively, p = 0.014]. The majority of patients (5.4% vs. 23.2%) developed a mild AKI (stage 1); severe damage (stage 3) occurred only in 1 patient in the control group (0.0% vs. 1.8%). No case of in-hospital renal failure requiring dialysis was reported. No significant differences in terms of mortality, cerebrovascular events, bleeding, and hospitalization for heart failure were noted in both groups at 30 days. Furosemide-induced diuresis with matched isotonic intravenous hydration using the RenalGuard system is an effective therapeutic tool to reduce the occurrence of AKI in patients undergoing TAVR. |
X Demographics
The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 2 | 67% |
| Canada | 1 | 33% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 2 | 67% |
| Scientists | 1 | 33% |
Mendeley readers
The data shown below were compiled from readership statistics for 151 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Japan | 2 | 1% |
| Colombia | 1 | <1% |
| Germany | 1 | <1% |
| Australia | 1 | <1% |
| Unknown | 146 | 97% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 22 | 15% |
| Other | 20 | 13% |
| Student > Bachelor | 16 | 11% |
| Student > Doctoral Student | 13 | 9% |
| Student > Ph. D. Student | 11 | 7% |
| Other | 32 | 21% |
| Unknown | 37 | 25% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 77 | 51% |
| Nursing and Health Professions | 10 | 7% |
| Agricultural and Biological Sciences | 3 | 2% |
| Pharmacology, Toxicology and Pharmaceutical Science | 3 | 2% |
| Computer Science | 2 | 1% |
| Other | 6 | 4% |
| Unknown | 50 | 33% |
Attention Score in Context
This research output has an Altmetric Attention Score of 174. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 19 August 2022.
All research outputs
#235,266
of 26,017,215 outputs
Outputs from JACC: Cardiovascular Interventions
#15
of 4,110 outputs
Outputs of similar age
#2,910
of 286,490 outputs
Outputs of similar age from JACC: Cardiovascular Interventions
#1
of 57 outputs
Altmetric has tracked 26,017,215 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 98th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 4,110 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 15.2. This one has done particularly well, scoring higher than 99% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 286,490 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 98% of its contemporaries.
We're also able to compare this research output to 57 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 98% of its contemporaries.